³Ô¹Ï±¬ÁÏ Commercial Cloud Selected by Idorsia
to Accelerate Digital Engagement Globally
³Ô¹Ï±¬ÁÏ provides leading-edge biopharmaceutical company
commercial foundation to launch innovative new medicines
PLEASANTON, CA ¡ª Sept. 21, 2020 ¡ª ³Ô¹Ï±¬ÁÏ Systems (NYSE: VEEV) today announced that Idorsia Pharmaceuticals Ltd (SIX: IDIA) has selected ³Ô¹Ï±¬ÁÏ Commercial Cloud to enable its digital field force in the U.S., Japan, and countries across Europe. Idorsia is at the forefront of innovative therapies and needed best-in-class cloud technology to drive its global commercial strategy. ³Ô¹Ï±¬ÁÏ Commercial Cloud brings together multichannel engagement, data, content, and analytics to give Idorsia the foundation for digital excellence.
¡°³Ô¹Ï±¬ÁÏ is an important partner that has helped us to rapidly scale-up, supporting our growth plans,¡± said Joseph Bejjani, CIO at Idorsia. ¡°³Ô¹Ï±¬ÁÏ Commercial Cloud streamlines commercial processes from pre-launch planning to execution and digitally enables our field force to more effectively engage customers.¡±
Adoption of ³Ô¹Ï±¬ÁÏ Commercial Cloud builds upon Idorsia¡¯s success with ³Ô¹Ï±¬ÁÏ Development Cloud in speeding end-to-end product development. Idorsia is a fast-growing biopharmaceutical company based in Switzerland with a broad portfolio of innovative drugs in its pipeline.
¡°Idorsia is a visionary company leading the way on digital transformation,¡± said Peter Gassner, founder and CEO of ³Ô¹Ï±¬ÁÏ. ¡°We¡¯re thrilled to expand our partnership with Idorsia and support their digital strategy as they prepare to bring new medicines to market and help more patients.¡±
Learn more about ³Ô¹Ï±¬ÁÏ Commercial Cloud at ³Ô¹Ï±¬ÁÏ Commercial & Medical Summit Online, Europe, November 17-18. The event is only open to life sciences industry professionals. Register for the virtual event at veeva.com/Summit.
Additional Information
For more on ³Ô¹Ï±¬ÁÏ Commercial Cloud, visit: veeva.com/CommercialCloud
Connect with ³Ô¹Ï±¬ÁÏ on LinkedIn:
Follow @veevasystems on Twitter:
Like ³Ô¹Ï±¬ÁÏ on Facebook:
About Idorsia
Idorsia Ltd is reaching out for more - We have more ideas, we see more opportunities and we want to help more patients. In order to achieve this, we will develop Idorsia into one of Europe¡¯s leading biopharmaceutical companies, with a strong scientific core.
Headquartered in Switzerland - a biotech-hub of Europe - Idorsia is specialized in the discovery and development of small molecules, to transform the horizon of therapeutic options. Idorsia has a broad portfolio of innovative drugs in the pipeline, an experienced team, a fully-functional research center, and a strong balance sheet ¨C the ideal constellation to bringing R&D efforts to business success.
Idorsia was listed on the SIX Swiss Exchange (ticker symbol: IDIA) in June 2017 and has over 800 highly qualified specialists dedicated to realizing our ambitious targets.
About ³Ô¹Ï±¬ÁÏ Systems
³Ô¹Ï±¬ÁÏ Systems Inc. is the leader in cloud-based software for the global life sciences industry. Committed to innovation, product excellence, and customer success, ³Ô¹Ï±¬ÁÏ serves more than 900 customers, ranging from the world¡¯s largest pharmaceutical companies to emerging biotechs. ³Ô¹Ï±¬ÁÏ is headquartered in the San Francisco Bay Area, with offices throughout North America, Europe, Asia, and Latin America. For more information, visit veeva.com.
Forward-looking Statements
This release contains forward-looking statements, including the market demand for and acceptance of ³Ô¹Ï±¬ÁÏ¡¯s products and services, the results from use of ³Ô¹Ï±¬ÁÏ¡¯s products and services, and general business conditions (including the on-going impact of COVID-19), particularly within the life sciences industry. Any forward-looking statements contained in this press release are based upon ³Ô¹Ï±¬ÁÏ¡¯s historical performance and its current plans, estimates, and expectations, and are not a representation that such plans, estimates, or expectations will be achieved. These forward-looking statements represent ³Ô¹Ï±¬ÁÏ¡¯s expectations as of the date of this press announcement. Subsequent events may cause these expectations to change, and ³Ô¹Ï±¬ÁÏ disclaims any obligation to update the forward-looking statements in the future. These forward-looking statements are subject to known and unknown risks and uncertainties that may cause actual results to differ materially. Additional risks and uncertainties that could affect ³Ô¹Ï±¬ÁÏ¡¯s financial results are included under the captions, ¡°Risk Factors¡± and ¡°Management¡¯s Discussion and Analysis of Financial Condition and Results of Operations,¡± in the company¡¯s filing on Form 10-Q for the period ended July 31, 2020. This is available on the company¡¯s website at veeva.com under the Investors section and on the SEC¡¯s website at . Further information on potential risks that could affect actual results will be included in other filings ³Ô¹Ï±¬ÁÏ makes with the SEC from time to time.
###
Contact:
³Ô¹Ï±¬ÁÏ Systems
pr@veeva.com